A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERAPEUTIC EFFICACY AND SAFETY OF AAV GENE THERAPY WITH VALOCTOCOGENE ROXAPARVOVEC FOR SEVERE HEMOPHILIA A
| Autor: | Ozelo, M.C., Pasi, K.J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C.B., Li, M., Kim, B., Pierce, G.F., Wong, W.Y. |
|---|---|
| Zdroj: | In Hematology, Transfusion and Cell Therapy November 2020 42 Supplement 2:60-60 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|